OrthoPediatrics Beheer
Beheer criteriumcontroles 3/4
De CEO OrthoPediatrics is David Bailey, benoemd in Jun2020, heeft een ambtstermijn van 4.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.72M, bestaande uit 18.4% salaris en 81.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.95% van de aandelen van het bedrijf, ter waarde $ 5.21M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 12.8 jaar.
Belangrijke informatie
David Bailey
Algemeen directeur
US$2.7m
Totale compensatie
| Percentage CEO-salaris | 18.4% |
| Dienstverband CEO | 4.4yrs |
| Eigendom CEO | 0.9% |
| Management gemiddelde ambtstermijn | 4.1yrs |
| Gemiddelde ambtstermijn bestuur | 12.8yrs |
Recente managementupdates
Recent updates
Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)
Nov 05
The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 09Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price
Aug 02OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets
May 09OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?
May 07Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
Apr 10Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S
Dec 20Getting In Cheap On OrthoPediatrics Corp. (NASDAQ:KIDS) Might Be Difficult
May 05OrthoPediatrics' (NASDAQ:KIDS) Earnings Aren't As Good As They Appear
Nov 08OrthoPediatrics announces public offering of stock, pre-funded warrants
Aug 10Is OrthoPediatrics (NASDAQ:KIDS) Using Debt In A Risky Way?
Aug 08OrthoPediatrics enters distribution agreement with 3D-Side
Jul 13Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$25m |
| Mar 31 2024 | n/a | n/a | -US$22m |
| Dec 31 2023 | US$3m | US$500k | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | US$976k |
| Mar 31 2023 | n/a | n/a | US$4m |
| Dec 31 2022 | US$1m | US$415k | US$1m |
| Sep 30 2022 | n/a | n/a | US$9m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$906k | US$371k | -US$16m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$33m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$898k | US$371k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$15m |
| Dec 31 2019 | US$836k | US$300k | -US$13m |
| Sep 30 2019 | n/a | n/a | -US$11m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$10m |
| Dec 31 2018 | US$590k | US$266k | -US$12m |
| Sep 30 2018 | n/a | n/a | -US$25m |
| Jun 30 2018 | n/a | n/a | -US$26m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$483k | US$258k | -US$24m |
Compensatie versus markt: De totale vergoeding ($USD 2.72M ) David } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.22M ).
Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.
CEO
David Bailey (45 yo)
4.4yrs
Tenure
US$2,721,840
Compensatie
Mr. David R. Bailey serves as the Chief Executive Officer at OrthoPediatrics Corp. since June 01, 2021. He serves as the President at OrthoPediatrics Corp. since June 3, 2020 and serves as its Director sin...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 15.8yrs | geen gegevens | 0.75% $ 4.1m | |
| President | 4.4yrs | US$2.72m | 0.95% $ 5.2m | |
| CFO, Principal Financial & Accounting Officer | 9.8yrs | US$2.04m | 0.62% $ 3.4m | |
| Executive VP of Legal | 15.8yrs | US$1.35m | 0.32% $ 1.8m | |
| President of Scoliosis | no data | US$1.35m | 0.48% $ 2.6m | |
| President of Enabling Technologies | 1.5yrs | US$22.50k | geen gegevens | |
| President of Trauma & Deformity Correction | 3.8yrs | US$1.35m | 0.37% $ 2.1m | |
| Senior Vice President of Clinical & Regulatory Affairs | 2.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of International Sales | 8.8yrs | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van KIDS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman | 15.8yrs | geen gegevens | 0.75% $ 4.1m | |
| President | 3yrs | US$2.72m | 0.95% $ 5.2m | |
| CFO, Principal Financial & Accounting Officer | 9.3yrs | US$2.04m | 0.62% $ 3.4m | |
| Lead Independent Director | 15.8yrs | US$185.00k | 0.086% $ 471.2k | |
| Chair of Surgeon Advisory Board | no data | geen gegevens | geen gegevens | |
| Director | 13.8yrs | US$180.00k | 0.10% $ 557.0k | |
| Independent Director | 12.8yrs | US$190.00k | 0.053% $ 291.0k | |
| Member of Surgeon Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Surgeon Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Surgeon Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Surgeon Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 10.8yrs | US$185.00k | 0.047% $ 257.9k |
12.8yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van KIDS zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.8 jaar).